We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-8.25%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$3.75B
AUM Growth
-$833M
(-18%)
Cap. Flow
-$27.3M
Cap. Flow
% of AUM
-0.73%
Top 10 Holdings %
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veru
VERU
|
+$91.7M |
| 2 |
PepGen
PEPG
|
+$90.7M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$66.8M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$36.2M |
| 5 |
Nkarta
NKTX
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$60.4M |
| 2 |
MacroGenics
MGNX
|
+$53.8M |
| 3 |
Novavax
NVAX
|
+$51M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$32.1M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.56% |
| 2 | Financials | 1.17% |
| 3 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$15.8B
| $704M | 18.76% |
7,567,900
| – | – |
|
2
Biogen
BIIB
$31.9B
| $148M | 3.95% |
727,024
| – | – |
|
3
Cytek Biosciences
CTKB
$636M
| $144M | 3.83% |
13,381,054
| – | – |
|
|
JBIO
4
Jade Biosciences
JBIO
$1.11B
| $129M | 3.44% |
236,114
| – | – |
|
|
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
| $126M | 3.36% |
7,040,622
+980,532
| +16% | +$10.1M |
|
6
Travere Therapeutics
TVTX
$5.89B
| $119M | 3.18% |
4,922,941
| – | – |
|
7
Janux Therapeutics
JANX
$1.01B
| $106M | 2.82% |
8,670,644
| – | – |
|
8
Vaxcyte
PCVX
$8.81B
| $99.7M | 2.66% |
4,581,203
| – | – |
|
|
IMGN
9
DELISTED
Immunogen Inc
IMGN
| $97.8M | 2.61% |
21,741,458
| – | – |
|
|
10
Nkarta
NKTX
$206M
| $96.2M | 2.56% |
7,805,129
+2,200,000
| +39% | +$28.9M |
|
|
BLU
11
DELISTED
BELLUS Health Inc.
BLU
| $94.5M | 2.52% |
10,230,274
| – | – |
|
|
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
| $91M | 2.43% |
4,417,259
| – | – |
|
|
13
Veru
VERU
$39.9M
| $89.3M | 2.38% |
+790,000
| New | +$91.7M |
|
|
DICE
14
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $80.8M | 2.16% |
5,208,911
| – | – |
|
|
15
PepGen
PEPG
$200M
| $80.8M | 2.15% |
+8,131,952
| New | +$90.7M |
|
|
FMTX
16
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $62.1M | 1.66% |
9,011,651
| – | – |
|
|
17
Aclaris Therapeutics
ACRS
$814M
| $61.4M | 1.64% |
4,398,453
+2,580,645
| +142% | +$36.2M |
|
|
PNT
18
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $61.3M | 1.63% |
9,003,018
| – | – |
|
19
Celldex Therapeutics
CLDX
$3.02B
| $55.9M | 1.49% |
2,075,000
| – | – |
|
20
Wave Life Sciences
WVE
$879M
| $55.9M | 1.49% |
17,202,009
+9,426,802
| +121% | +$18.1M |
|
21
Vor Biopharma
VOR
$1.32B
| $55.3M | 1.47% |
556,049
| – | – |
|
|
KNTE
22
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $53.8M | 1.43% |
4,264,144
| – | – |
|
23
Tyra Biosciences
TYRA
$1.52B
| $51.7M | 1.38% |
7,236,454
| – | – |
|
24
GH Research
GHRS
$1.89B
| $48.9M | 1.3% |
4,898,373
+71,043
| +1% | +$923K |
|
25
Geron
GERN
$842M
| $46.7M | 1.25% |
30,126,299
| – | – |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, RA Capital Management held 110 positions worth $3.75B, down 18% from $4.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
RA Capital Management's Q2 2022 filing shows 14 new, 9 increased, 11 reduced and 22 closed positions. Its largest new stake was Veru: 790,000 shares worth $89.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $60.4M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.
- RA Capital Management's largest Q2 2022 buy was Veru: 790,000 shares worth $89.3M.
- RA Capital Management added most to Aclaris Therapeutics in Q2 2022, an estimated $36.2M increase.
- RA Capital Management's biggest Q2 2022 reduction was LianBio American Depositary Shares, cutting an estimated $10.3M.
- RA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $60.4M.
- RA Capital Management's ten largest holdings make up 47% of its $3.75B portfolio in Q2 2022.
- RA Capital Management opened 14 new positions and closed 22 in Q2 2022.
- RA Capital Management's portfolio value fell 18% quarter-over-quarter to $3.75B.
Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.